Get started
Author

Mark Koester

Observed institution: Sapience Therapeutics
ORCID: 0000-0003-4559-6568
Observed ORCID: 0000-0003-4559-6568
OpenAlex ID: A5044206005
Anticancer Activity of ST101, A Novel Antagonist of CCAAT/Enhancer Binding Protein β
2022 · Emad Darvishi, Lila Ghamsari, et al. · Molecular Cancer Therapeutics · 22
PDF
The C/EBPβ antagonist peptide lucicebtide (ST101) induces macrophage polarization toward a pro-inflammatory phenotype and enhances anti-tumor immune responses
2025 · Claudio Scuoppo, Rick Ramirez, et al. · Frontiers in Immunology · 11
Abstract 5332: ST316, a clinical peptide antagonist of beta-catenin, induces anti-tumor immune responses by multiple mechanisms of action
2024 · Claudio Scuoppo, Karen Mendelson, et al. · Cancer Research · 3
Abstract B149: Anti-tumor and immunostimulatory properties of ST316, a peptide antagonist of beta-catenin for treatment of cancers with aberrant Wnt pathway activity
2023 · Lila Ghamsari, Claudio Scuoppo, et al. · Molecular Cancer Therapeutics · 3
Abstract LB016: Immunotherapeutic potential of ST316, a peptide antagonist of β-catenin
2023 · Claudio Scuoppo, Lila Ghamsari, et al. · Cancer Research · 3
Abstract B114: Clinical-stage Wnt/β-catenin antagonist peptide ST316, suppresses colorectal cancer tumor growth by promoting BCL9 degradation
2025 · Lila Ghamsari, Franco Abbate, et al. · Molecular Cancer Therapeutics · 1
1451 ST316, a peptide antagonist of β-Catenin, depletes immunosuppressive myeloid cell populations and enhances anti-cancer immune responses in in vivo tumor models and in patients
2024 · Claudio Scuoppo, Ricardo Ramirez, et al. · Journal for ImmunoTherapy of Cancer · 1
Abstract LB045: β-catenin antagonist peptide, ST316, attenuates Wnt-dependent oncogenic activity
2022 · Lila Ghamsari, Erin Gallagher, et al. · Cancer Research · 1
Targeted antagonism of the Activator Protein 1 transcription factor complex results in potent anti-tumor activity in HNSCC and NSCLC models
2026 · Karen Mendelson, Zachary F. Mattes, et al. · Code Ocean
Synergistic anti-tumor activity of EGFR inhibition and C/EBPβ antagonism in GBM
2026 · Julia Diehl, Claudio Scuoppo, et al. · bioRxiv (Cold Spring Harbor Laboratory)
Abstract 4767: Targeted antagonism of the activator protein 1 transcription factor complex results in potent anti-tumor activity in HNSCC models
2026 · Karen Mendelson, Zachary F. Mattes, et al. · Cancer Research
1198 Antagonism of beta-catenin/Bcl9 impairs generation of immune-suppressive MDSCs and promotes enhanced immune responses
2025 · Claudio Scuoppo, Julia Diehl, et al. · Journal for ImmunoTherapy of Cancer
PDF
Abstract 839: The clinical C/EBPβ antagonist peptide lucicebtide synergizes with molecularly targeted therapies in GBM
2025 · Julia Diehl, Ricardo Ramirez, et al. · Cancer Research
Abstract 1415: FraAP, a peptide antagonist against the activator protein 1 transcription factor complex, demonstrates cancer cell cytotoxicity and reduced invasion in vitro and tumor regression in vivo in HNSCC models
2025 · Karen Mendelson, Zachary F. Mattes, et al. · Cancer Research
Abstract 2361: An ex vivo organoid study to identify biomarkers of sensitivity to ST316, a clinical-stage β-catenin antagonist peptide
2025 · Franco Abbate, Lila Ghamsari, et al. · Cancer Research
Abstract 2909: ST101, a clinical CEBPβ antagonist peptide, promotes an immune-active tumor microenvironment by multiple cellular mechanisms
2024 · Claudio Scuoppo, Julia Diehl, et al. · Cancer Research
Abstract 3051: JunAP, a peptide antagonist against the activator protein 1 transcription factor complex, demonstrates cancer cell cytotoxicity and reduced invasion in vitro and tumor regression in vivo in TNBC models
2024 · Karen Mendelson, Zachary F. Mattes, et al. · Cancer Research
Supplementary Table from Anticancer Activity of ST101, A Novel Antagonist of CCAAT/Enhancer Binding Protein β
2023 · Emad Darvishi, Lila Ghamsari, et al.
Supplementary Data from Anticancer Activity of ST101, A Novel Antagonist of CCAAT/Enhancer Binding Protein β
2023 · Emad Darvishi, Lila Ghamsari, et al.
Supplementary Table from Anticancer Activity of ST101, A Novel Antagonist of CCAAT/Enhancer Binding Protein β
2023 · Emad Darvishi, Lila Ghamsari, et al.
Supplementary Data from Anticancer Activity of ST101, A Novel Antagonist of CCAAT/Enhancer Binding Protein β
2023 · Emad Darvishi, Lila Ghamsari, et al.
Data from Anticancer Activity of ST101, A Novel Antagonist of CCAAT/Enhancer Binding Protein β
2023 · Emad Darvishi, Lila Ghamsari, et al.
Data from Anticancer Activity of ST101, A Novel Antagonist of CCAAT/Enhancer Binding Protein β
2023 · Emad Darvishi, Lila Ghamsari, et al.
Abstract LB206: Characterizing the PK/PD relationship of C/EBPβ antagonist peptide ST101 in a mouse orthotopic breast cancer model
2022 · Jim Rotolo, Mark Koester, et al. · Cancer Research
Abstract P5-08-08: C/EBPβ antagonist peptide, ST101, as a novel therapeutic for breast cancer
2022 · Jim Rotolo, Mark Koester, et al. · Cancer Research
Works count: 32
Citation count: 45
H-index: 3
I10-index: 2
Year
Topic
Type